Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282984 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT00282984: Completed Phase 3 study of Smoking Cessation, sponsored by Pfizer.
NCT00282984 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 714 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282984, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
Primary Outcome
Participants considered Responders (4-week CQR \<=10 parts per million \<ppm\>) through reports of cigarette or other nicotine use since last study visit, confirmed by measurement of end-expiratory exhaled carbon monoxide (CO). If any CO measurement at a particular timepoint was \>10 ppm, subject was considered to be Non-Responder at that timepoint.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Varenicline
Study Locations (20)
Other
- Pfizer Investigational Site - Brno
- Pfizer Investigational Site - Prague
- Pfizer Investigational Site - Aarhus C
- Pfizer Investigational Site - Hellerup
- Pfizer Investigational Site - Caen
- Pfizer Investigational Site - Marseille
- Pfizer Investigational Site - Toulouse
Buenos Aires
- Pfizer Investigational Site - Capital Federal
- Pfizer Investigational Site - Ciudad de Buenos Aires
Ontario
- Pfizer Investigational Site - London
- Pfizer Investigational Site - Ottawa
Quebec
- Pfizer Investigational Site - Drummondville
- Pfizer Investigational Site - Québec
Connecticut
- Pfizer Investigational Site - Hartford
Massachusetts
- Pfizer Investigational Site - Boston
Wisconsin
- Pfizer Investigational Site - Madison
New South Wales
- Pfizer Investigational Site - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
What the finished NCT00282984 record still lists
NCT00282984 is an interventional study that assigns participants to a tested intervention. The registered 714 participants enrollment target is mid-sized for trials with a published cap, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (52% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00282984 names 20 study sites across 11 states, led by Other, Buenos Aires, Ontario.
Frequently Asked Questions
What is clinical trial NCT00282984 about?
NCT00282984 is a clinical study titled "Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking". The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
What is the current status of trial NCT00282984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 714 participants. The study started on 2006-02. Estimated completion is 2008-08.
What conditions does trial NCT00282984 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00282984?
The interventions under investigation include: placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00282984?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00282984 being conducted?
This trial has 20 study locations across Connecticut, Massachusetts, Wisconsin, Buenos Aires, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00282984's enrollment target sits among peer trials
714 37th of 188 higher than 152 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia